Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laurus Labs's dividends per share for the
three
months ended in Jun. 2026 was ₹1.20. Its dividends per share for the trailing twelve months (TTM) ended in Jun. 2026 was ₹2.00. Its Dividend Payout Ratio for the
three
months ended in Jun. 2026 was 0.18. As of today, Laurus Labs's Dividend Yield % is 0.11%.
Warning Sign:
Laurus Labs Ltd stock Dividend Yield % is close to 10-year low.
During the past 12 months, Laurus Labs's average Dividends Per Share Growth Rate was 66.70% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was -7.20% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was -4.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Laurus Labs was 74.70% per year. The lowest was -20.60% per year. And the median was 27.00% per year.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
During the past 13 years, the highest Dividend Payout Ratio of Laurus Labs was 0.58. The lowest was 0.08. And the median was 0.13.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
Laurus Labs Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
INR 1.200000
2026-05-08
2026-05-08
2026-05-20
Cash Dividend
semi-annually
INR:INR 1.000000
INR 0.800000
2025-10-31
2025-10-31
2025-11-12
Cash Dividend
semi-annually
INR:INR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Laurus Labs's Dividend Yield (%) for Today is calculated as
Current Share Price is ₹1814.95.
Laurus Labs's Dividends per Share for the trailing twelve months (TTM) ended in Today is ₹2.
During the past 13 years, the highest Dividend Yield of Laurus Labs was 0.88%. The lowest was 0.11%. And the median was 0.34%.
Warning Sign:
Laurus Labs Ltd stock Dividend Yield % is close to 10-year low.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laurus Labs Dividends per Share Related Terms
Laurus Labs Dividends per Share Historical Data
* Premium members only.
The historical data trend for Laurus Labs's Dividends per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laurus Labs Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Laurus Labs's Dividend Yield % falls into.
Laurus Labs (BOM:540222) has a Dividends per Share of ₹2.00 as of Jun. 2026. Dividends per share represents the per-share amount paid as dividends. View historical data on Laurus Labs and its competitors.
Is Laurus Labs' Dividends per Share too high?
Laurus Labs' current Dividends per Share is ₹2.00. Overall, Laurus Labs has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laurus Labs' Dividends per Share compare to ZTS?
Laurus Labs' Dividends per Share of ₹2.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Drug Manufacturers company?
A good Dividends per Share depends on the Drug Manufacturers industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Laurus Labs and its competitors. Laurus Labs's current Dividends per Share is ₹2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laurus Labs stock overvalued right now?
Based on GuruFocus' analysis, Laurus Labs (BOM:540222) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹840.33, compared to a current price of ₹1,814.95 — trading 116% above its estimated fair value. The current Dividends per Share is ₹2.00. Laurus Labs' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Laurus Labs (BOM:540222), the current Dividends per Share is ₹2.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laurus Labs (BOM:540222) Overvalued in 2026?
Based on GuruFocus' analysis, Laurus Labs stock appears to be overvalued.
The current stock price of ₹1,814.95 is trading 116% above its estimated GF Value™ of ₹840.33.
GuruFocus considers Laurus Labs to be Significantly Overvalued.
Key valuation signals for BOM:540222:
Dividends per Share: ₹2.00
GF Value™: ₹840.33 vs. price of ₹1,814.95 (116% above fair value)
No single metric tells the full story. See the BOM:540222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. The company generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
66GF Score
Get the complete analysis for BOM:540222
Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540222 has been successfully added to your 
